Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02152982 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

447

Enrollment

NIH

Sponsor class

Conditions

Glioblastoma
Gliosarcoma

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Placebo Administration
OTHER: Quality-of-Life Assessment
DRUG: Temozolomide
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)